cureVision
cureVision develops an AI-driven, MDR-certified 3D wound analysis medical device (cv.MESH) that automates chronic wound documentation for hospitals, nursing homes, and home care providers in Germany, with active U.S. expansion via BioLab Holdings.
- Company typePrivate
- Founded2021
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What cureVision does
cureVision GmbH is a German health technology company founded in 2021 in Munich and Potsdam that develops an AI-driven, MDR-certified medical device system for chronic wound documentation and analysis. The core product, the cv.MESH device, combines multiple sensors — RGB camera, depth sensor, thermal imaging, and multispectral fluorescence imaging — to perform contactless, automated 3D wound measurement and tissue composition analysis in approximately two minutes per documentation, compared with roughly 20 minutes using conventional paper-ruler methods. The platform includes three subscription tiers (ESSENTIAL, PROFESSIONAL, PREMIUM), optional modules (BacteriaScan for bacterial contamination detection, ThermoScan for thermal abnormality detection, prescription recommendation), a web-based management platform (cureVision Web), and a hospital integration layer (cureVision Connect) supporting FHIR, HL7, GDT, and REST protocols.
The company sells primarily to hospitals and clinics, nursing homes and outpatient care services, and home care and wound management providers in the DACH region, with a stated go-to-market that combines direct enterprise sales, inside sales/demo booking, channel partners (notably BioLab Holdings for U.S. market entry announced in September 2025), event participation at wound fairs, and content marketing through whitepapers and case studies. Named customers include Klinikum Nürnberg, Spörer AG, Bürgerspital Landau, AGM Müller, Wundversorgung Otto, PROLIFE, PHV, Pflegedienst Engel vonne Ruhr, Sozialstation Herbert Hildebrand, Pflegeteam Geisel, and Noracare. The company is GDPR-compliant with data stored exclusively on German servers, has been recognized with multiple innovation awards (Innovationspreis Bayern 2024, Health-i Award 2023, Digitaler Gesundheitspreis 2023, Eugen Münch Preis 2023, German Startup and Digitalization Prize 2022), and has raised approximately $2.9M+ across funding rounds from 2021 through 2024 with a strategic investment from BioLab Holdings in 2025 to support U.S. market expansion, FDA clearance pursuit, and commercialization.
cureVision firmographics
Firmographics- Name
- cureVision
- Legal name
- cureVision GmbH
- Website
- https://curevision.de
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- cureVision develops an AI-driven, MDR-certified 3D wound analysis medical device (cv.MESH) that automates chronic wound documentation for hospitals, nursing homes, and home care providers in Germany, with active U.S. expansion via BioLab Holdings.
- Ownership category
- akta.pro rank
cureVision industry classification
Industry- Product category
- Medical Imaging and Wound Care Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Wound Care & Ulcer Management (HLAKACAN)
- akta.pro secondary industries
- Wound Care & Diabetic Foot Infection (HLAKAGAK), Home-Based Wound Care & Ostomy Nursing (HLADAFAH), Complex Wound Care SNFs (HLADADAJ), Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK)
Keywords
Where cureVision is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
cureVision business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Software Subscription (Tiered): Three-tier subscription model: ESSENTIAL (up to 10 patients), PROFESSIONAL (unlimited patients with telephone support), and PREMIUM (large facilities with advanced features). All tiers include base wound analysis features with optional add-ons like BacteriaScan and prescription recommendation. Plus one-time setup fee.
- Hardware Device Sales: Sale of cv.MESH hardware device - MDR-certified wound analysis device. Hardware is required to use the software platform. Sold as part of initial system setup.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Up to 10 patients, essential wound documentation features |
| Subscription | Monthly | Unlimited patients, telephone support, secure report sharing, editing from any device |
| Subscription | Monthly | Large teams, full customization, internal quality control, location management, FHIR integration |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels9 records
cureVision product offering
Product offeringCore offering
cureVision develops and sells an MDR-certified AI-driven 3D wound analysis system consisting of the cv.MESH handheld multi-sensor hardware device (RGB camera, depth sensor, thermal camera, multispectral imaging) and cloud-based software for fully automated wound measurement, tissue analysis, bacterial detection, and digital wound documentation. The solution is offered to hospitals, nursing homes, and home care providers under tiered monthly subscriptions with optional add-on modules (BacteriaScan, ThermoScan, prescription recommendation) and a one-time setup fee.
Product overview
cureVision offers a unified medical device ecosystem for AI-driven wound analysis and digital documentation, centered on the cureVision® System (cv.MESH) — an MDR-approved handheld device that performs fully automated 3D wound assessment combining RGB imaging, infrared thermography (ThermoScan), and multispectral bacterial fluorescence detection (BacteriaScan). The core system is augmented by two cloud/web components: cureVision® Web provides a PC-based platform for centralized wound report management, editing, approval workflows, and multi-location administration; and cureVision Connect enables KIS/HIS integration via FHIR or GDT protocols. Three subscription tiers (ESSENTIAL, PROFESSIONAL, PREMIUM) provide escalating access to features including the optional Prescription Recommendation module. The company also recently announced a strategic partnership with BioLab Holdings to enter the U.S. market.
Differentiator
Problem solved
Functional benefit
Brands
- BacteriaScan: AI-powered bacterial contamination detection feature using fluorescence imaging to identify areas with increased bacterial load in wounds
- ThermoScan
- cureVision Web
- cureVision Connect
Products and services
- cureVision® System (cv.MESH) The primary MDR-approved medical device for automated 3D wound analysis. Combines multiple sensors (RGB camera, depth sensor, thermal camera, multispectral imaging) with AI to analyze wound size, depth, tissue types, temperature, and bacterial load at the push of a button. Disinfectable, fall-proof hardware that performs contact-free analysis 10x faster than manual methods, reducing documentation time from ~20 minutes to ~2 minutes. Sold to hospitals, nursing homes, and home care providers as part of the initial system setup.
- cureVision® BacteriaScan Multispectral imaging module that detects bacterial contamination in and around wounds using violet LED-induced fluorescence to highlight porphyrin and pyoverdin metabolites. Visualizes bacterial load in red or green fluorescence, enabling early infection detection, targeted swab collection, and optimized wound cleansing. Detects bacterial loads from approximately 10^4 CFU/g and works in daylight conditions without full room darkening. Available as an add-on on the PROFESSIONAL and PREMIUM tiers.
- cureVision® ThermoScan Infrared thermography module integrated into the cv.MESH device for early detection of abnormal thermal patterns indicating inflammation (positive temperature gradient), ischemia, or necrosis (negative temperature gradient). Generates thermal images within seconds to track wound healing progress and predict pressure ulcer development before tissue damage becomes visible on intact skin.
- cureVision® Web Web-based platform for managing wound reports, editing documentation on PC, and administering the cureVision system. Enables centralized patient data management, digital patient file maintenance, dashboard views of wound healing progress, calendar tracking for due documentation, role-based approval workflows for quality control, multi-location management, customizable assessment questionnaires, and secure sharing of wound reports with healthcare providers.
- cureVision Connect Interface module enabling integration of the cureVision system into hospital information systems (KIS/HIS) via FHIR, HL7, REST, or GDT (Geräte-Datenträger-Transfer) protocols. Allows wound reports to be transferred directly into patient files automatically. Existing interfaces available with acriba and HalloAlberta industry software. Available on the PREMIUM tier for an additional charge, with FHIR integration priced by individual agreement.
Quantifiable outcome
- 90% time reduction in wound documentation (from 20 minutes to 2 minutes)
- +3 more outcomes
Companies that use cureVision
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
cureVision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability8 records
Feature8 records
cureVision partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- BioLab HoldingscoreStrategic investment and partnership to introduce cureVision's AI-driven wound assessment technology in the U.S. market. BioLab provides distribution network, regulatory approval support, reimbursement expertise, and commercialization capabilities. Aimed at accelerating cureVision's FDA approval and market entry in the United States.
- Strascheg Center for Entrepreneurship (SCE)coreSupported cureVision from early stages. Recognized company's potential and provided support through startup incubation program. CureVision won multiple awards through SCE connections including Health-i-Award 2023.
- EIT HealthcoreEuropean Institute of Innovation and Technology Health program recognized cureVision's potential and provided support. Part of innovation ecosystem helping healthcare startups scale.
- Angels4HealthcoreHealthcare innovation network that recognized cureVision's potential and provided backing. Supports company on mission to improve treatment and quality of life for chronic wound patients.
- TUM Venture LabsminorTechnology and startup support organization affiliated with Technical University of Munich. Provides resources and connections for technical startups in healthcare.
- AI MunichminorMunich-based AI innovation network supporting AI companies in the region. Partnership supports cureVision's AI development initiatives.
- Federal Ministry for Economic Affairs (Bundesministerium für Wirtschaft)coreGerman federal government ministry providing funding and support for innovative technology companies. Supports cureVision's development of medical technology solutions.
- Munich University of Applied Sciences (Hochschule München)minorAcademic partnership providing research collaboration and access to talent. HM alumni successfully developed cureVision with AI-powered wound analysis.
- 5-HT Chemistry & HealthminorChemistry and healthcare innovation platform connecting startups with industry partners. cureVision featured as revolutionary wound documentation solution.
- LuminateminorHealth tech accelerator and support organization. Part of cureVision's partner ecosystem for growth and scaling.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
cureVision competitors and assessment
Company assessmentDirect peers
- MolecuLight: MolecuLight's i:X and DX fluorescence imaging devices detect bacterial load in wounds, directly mirroring cureVision's BacteriaScan capability. Both sell point-of-care imaging hardware to wound care clinicians for infection detection.
- Swift Medical: Swift Medical (Swift Skin and Wound) is a direct competitor offering AI-powered wound imaging and measurement for clinicians. Both companies target the same nurse and wound-care workflow with smartphone or device-based automated wound assessment.
- Tissue Analytics (a Net Health company): Tissue Analytics, now part of Net Health, offers a digital wound care platform with AI-driven imaging and EHR integration. It competes directly with cureVision Web and cureVision Connect in hospital and post-acute wound documentation.
- Aranz Medical (Silhouette): Aranz Medical's Silhouette system is a regulated 3D wound measurement and documentation device used in clinical trials and wound care clinics. It is directly comparable to cv.MESH in offering validated 3D wound measurement for healthcare providers.
- WoundZoom: WoundZoom provides tablet-based digital wound measurement and documentation for hospitals and long-term care facilities, overlapping with cureVision's hospital and nursing home target segments.
- eKare Inc. eKare provides AI-based 3D wound measurement and tissue analysis (eKare Insight) with iPad-based hardware. It is one of the closest direct peers to cureVision in AI-driven wound documentation and analytics.
Emerging players
- Healthy.io: Healthy.io applies smartphone-based computer vision to clinical diagnostics (kidney disease, wound care). Its wound offering and smartphone imaging approach make it a partial overlap with cureVision's AI wound assessment strategy.
Broad incumbents
- Smith & Nephew: Smith & Nephew's Global Wound Care division sells advanced wound dressings and adjunctive digital wound management tools to the same hospitals and home care channels that cureVision targets. It is a broad incumbent rather than a niche specialist.
- Mölnlycke Health Care: Mölnlycke is a major global wound care and surgical solutions company with Mepilex and other wound products. Its bundled dressing-plus-digital strategy and existing hospital relationships make it a broad incumbent that could expand into wound imaging.
- Net Health (Tissue Analytics parent): Net Health is a specialized EHR and analytics provider for wound care, physical therapy, and occupational health. Through Tissue Analytics it offers digital wound imaging that competes with cureVision, and its broader specialty EHR suite makes it an incumbent in the same customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
cureVision social profiles
Digital presencecureVision compliance and trust
Trust signalCompliance3 records
cureVision financial estimates
Financial estimateRevenue estimate
Valuation estimate
cureVision leadership team
Management profileNumber of profiles
Profiles3 records
cureVision funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
cureVision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about cureVision
What does cureVision do?
cureVision develops and sells an MDR-certified AI-driven 3D wound analysis system consisting of the cv.MESH handheld multi-sensor hardware device (RGB camera, depth sensor, thermal camera, multispectral imaging) and cloud-based software for fully automated wound measurement, tissue analysis, bacterial detection, and digital wound documentation. The solution is offered to hospitals, nursing homes, and home care providers under tiered monthly subscriptions with optional add-on modules (BacteriaScan, ThermoScan, prescription recommendation) and a one-time setup fee.
Is cureVision a public or private company?
cureVision is a private company. It is classified as venture growth investor backed and is currently operating.
When was cureVision founded?
cureVision was founded in 2021. It employs 11 to 50 people.
Where is cureVision based?
cureVision is headquartered in Munich, Germany, in the Europe region.
How does cureVision make money?
Two revenue lines are on record. Software Subscription (Tiered) is the primary driver. The others are hardware Device Sales.
Who are cureVision's main competitors?
Direct peers on record are MolecuLight, Swift Medical, Tissue Analytics (a Net Health company), Aranz Medical (Silhouette), WoundZoom and eKare Inc.. Healthy.io is listed as an emerging player. Broad incumbents are Smith & Nephew, Mölnlycke Health Care and Net Health (Tissue Analytics parent).
Does cureVision have an API?
Yes. cureVision offers integration via established standards including HL7, HL7 FHIR, and REST. Existing interfaces exist in industry software such as acriba and Hallo Alberta. cureVision Connect enables integration into hospital information systems (KIS/HIS) via FHIR or GDT (Geräte-Datenträger-Transfer) protocols. Integration is priced by individual agreement for an additional charge on the PREMIUM tier.
What industry is cureVision in?
cureVision's product category is Medical Imaging and Wound Care Software. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management, with a secondary code of HLAKAGAK, Wound Care & Diabetic Foot Infection. Its NAICS code is 334510 and its SIC code is 3841.